Zantac Generics MDL Labeling Claims Axed As Preempted

Law360 (January 4, 2021, 4:44 PM EST) -- A Florida federal judge presiding over sprawling multidistrict litigation over the carcinogens found in the popular heartburn medication Zantac has held that state labeling and design defect claims against Zantac generics makers, repackagers, retailers and distributors are preempted by federal law.

In separate Dec. 31 orders, U.S. District Judge Robin L. Rosenberg dismissed the state product liability claims against 32 Zantac generics makers, retailers and distributors, finding that they're preempted because those entities cannot independently alter brand-name drug labels or designs and still comply with labels approved by the U.S. Food and Drug Administration. The judge also rejected allegations that the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!